Abstract
Helicobacter pylori is a gram-negative bacterium that chronically infects the gastric epithelium. Potassium-competitive acid blockers (P-CABs) are a promising alternative, being more potent than standard proton pump inhibitors (PPIs). The meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Inclusion criteria were randomized controlled trials (RCTs) comparing P-CAB and PPI-based therapy, confirmed H. pylori infection, and measured eradication rates after at least four weeks. Subgroup analyses were conducted based on therapy type and trial location. Quality assessment used the Cochrane risk-of-bias tool, RoB 2.0, and statistical analysis was performed using ReviewManager (RevMan) 5.4 (2020; The Cochrane Collaboration, London, United Kingdom). A p-value of <0.05 is considered statistically significant. In the intention-to-treat (ITT) analysis, P-CABs demonstrated superior overall efficacy, consistently observed in the first-line treatment subgroup. However, no significant difference was found in the subgroup receiving salvage therapy. Another ITT subgroup analyzed the impact of geographical location, favoring P-CABs in the overall study population and the Japanese subgroup. However, no statistically significant differences were found in the subgroups of other countries. In the PPA, P-CABs showed superior efficacy overall, consistently seen in the first-line treatment subgroup. However, no significant difference was found in the subgroup receiving salvage eradication therapy. Another PPA subgroup analysis considered the geographical impact on eradication rates, revealing P-CABs as superior to PPIs in the overall study population and the Japanese subgroup, but not in other countries. No significant adverse event outcomes were observed. P-CAB-based triple therapy is more effective than PPI-based triple therapy as the primary treatment for H. pylori eradication, particularly in Japanese patients. Nevertheless, regarding salvage therapy, both treatments show comparable efficacy. Additionally, the tolerability of P-CAB-based and PPI-based triple therapy is similar, with a similar occurrence of adverse events.
Keywords: randomized clinical trials, meta-analysis, systematic review, helicobacter pylori, eradication, proton pump inhibitors, potassium-competitive acid blockers
Introduction and background
Helicobacter pylori is a gram-negative, microaerophilic bacterium. It possesses distinct adaptations to chronically infect the luminal surface of the gastric epithelium [1]. The global prevalence of H. pylori infection is estimated to be around 50%, while in the United States, it is approximately 35-40%. H. pylori has been found to be linked to the pathogenesis of many gastroduodenal disorders [2], encompassing gastric and duodenal ulcers, gastric cancer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma [3-5], and gastritis [6]. Both the Maastricht V Consensus Report [7] and the Kyoto Global Consensus Report [8] acknowledge H. pylori-associated gastritis as an infectious ailment, although the World Health Organization (WHO) has classed it as a carcinogenic agent [9]. The role of H. pylori in stomach cancer has been widely accepted for over 30 years [10], and emerging evidence suggests that eradicating H. pylori may decrease the incidence of gastric cancer [11-13]. The acquisition of H. pylori is predominantly observed during childhood [14], and its progression extends over several decades [15]. Therefore, testing young adults for H. pylori and eradicating it in those who test positive is a rational way to lower the risk of stomach cancer [16].
The development of a widely accepted H. pylori treatment remains challenging. However, all interventions aim to reduce infectious symptoms and recover mucosal integrity [17]. Primary and secondary H. pylori treatments with proton-pump inhibitors (PPIs) are common. However, standard treatment methods, which necessitate acid suppression and numerous antibiotics, have efficacy rates that have fallen below the deemed acceptable level of 80% worldwide [18]. The decrease in the efficiency of treatment is impacted by various factors, including antibiotic resistance, level of acid suppression, and several host and bacterial variables [19-21]. It is worth noting that in areas with clarithromycin resistance, current expert clinical practice guidelines no longer recommend normal clarithromycin-based triple therapy as the primary empirical treatment [22-24]. In 2017, the WHO declared H. pylori a high-priority bacterium due to the problem at hand. This designation was created to encourage scientific research and advance new approaches to treatment [25].
Potassium-competitive acid blockers (P-CABs) function by selectively and reversibly blocking the enzyme H+/K+-ATPase, effectively reducing the production of gastric acid. Their efficacy is dose-dependent, as they engage in competitive interactions with potassium ions [26]. They demonstrate a greater ability to suppress acid for a longer duration, and their impact on the CYP2C19 system is somewhat lower when compared to PPIs [27-29]. The potency of these substances exceeds that of conventional PPIs by a ratio of 350 [30,31]. Clinical research undertaken in Japan showed that P-CABs had distinct advantages over PPIs in terms of eradicating H. pylori [32]. Since 2015, the product has been made accessible in Japan and has also been released in a restricted number of other Asian nations [27,33-35] for the purpose of treating H. pylori. Recent meta-analytic studies have demonstrated the comparative advantage of therapy incorporating P-CABs in comparison to those of PPIs [36-38]. Nevertheless, the findings of this study have diverged from those of previous research [39-42]. Consequently, we have conducted a meta-analysis that explicitly included randomized controlled trials (RCTs) in order to assess the effectiveness and safety of P-CAB-based therapy for the eradication of H. pylori.
Review
Methods
Our meta-analysis adhered to the guidelines set by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [43].
Search Strategy
A systematic search was conducted on the Cochrane Library, Embase, Scopus, PubMed, and Google Scholar from inception until September 20, 2023, for RCTs that evaluated the eradication rate of H. pylori. The following key terms and words, or their equivalents, were utilized: "potassium-competitive acid blocker," "vonoprazan," "takecab," "TAK438," "Helicobacter pylori," "H. pylori," "Hp," and "Proton pump inhibitors," in conjunction with the Boolean operators "AND" and "OR." There were no restrictions imposed on time or language. Details of the search strategy employed can be found in Table 1.
Table 1. Search Strategy Table.
| Database | Query | Search details | Results |
| PubMed | (potassium-competitive acid blocker OR vonoprazan OR takecab OR TAK438) AND (Helicobacter pylori OR H. pylori OR Hp) AND (Proton pump inhibitors) | (("potassium-competitive"[All Fields] AND ("acids"[MeSH Terms] OR "acids"[All Fields] OR "acid"[All Fields]) AND ("blocker"[All Fields] OR "blocker s"[All Fields] OR "blockers"[All Fields])) OR ("1 5 2 fluorophenyl 1 pyridin 3 ylsulfonyl 1h pyrrol 3 yl n methylmethanamine"[Supplementary Concept] OR "1 5 2 fluorophenyl 1 pyridin 3 ylsulfonyl 1h pyrrol 3 yl n methylmethanamine"[All Fields] OR "vonoprazan"[All Fields]) OR "takecab"[All Fields] OR ("1 5 2 fluorophenyl 1 pyridin 3 ylsulfonyl 1h pyrrol 3 yl n methylmethanamine"[Supplementary Concept] OR "1 5 2 fluorophenyl 1 pyridin 3 ylsulfonyl 1h pyrrol 3 yl n methylmethanamine"[All Fields] OR "tak438"[All Fields])) AND ("helicobacter pylori"[MeSH Terms] OR ("helicobacter"[All Fields] AND "pylori"[All Fields]) OR "helicobacter pylori"[All Fields] OR ("helicobacter pylori"[MeSH Terms] OR ("helicobacter"[All Fields] AND "pylori"[All Fields]) OR "helicobacter pylori"[All Fields] OR "h pylori"[All Fields]) OR "Hp"[All Fields]) AND ("proton pump inhibitors"[Pharmacological Action] OR "proton pump inhibitors"[MeSH Terms] OR ("proton"[All Fields] AND "pump"[All Fields] AND "inhibitors"[All Fields]) OR "proton pump inhibitors"[All Fields]) | 204 |
| Embase | 30 | ||
| Cochrane Library | 18 | ||
| SCOPUS | 29 | ||
| Google Scholar | 45 |
Inclusion and Exclusion Criteria
To establish the study's eligibility, two reviewers independently examined pertinent literature. A third reviewer was consulted to reach a consensus in the event of differences. Our inclusion criteria encompass RCTs that compare P-CAB and PPI-based therapy as the main treatment for H. pylori eradication, H. pylori infection confirmed (by one or more confirmatory tests), the eradication rate measured using intention-to-treat (ITT) and per-protocol (PP) analyses at least four weeks after treatment completion and confirmed H. pylori eradication. The criteria for exclusion were observational studies and non-RCTs, absence of pertinent data, publications with abstracts only, unpublished research, non-English language, and unmeasured eradication rate.
Data Extraction and Measures of Outcomes
The following data were extracted by two independent researchers: name of the first author, publication year, country, study period, eradication regimens, eradication rate, dropout rate, and adverse events. Risk ratios and 95%CI were calculated from this data.
The outcomes of our study depend on the comparison of the rates of H. pylori eradication between two cohorts, the group administered with P-CAB, and the group administered with PPI. Both the ITT and PPA methodologies were employed to evaluate the rates in question. Furthermore, subgroup analyses were undertaken based on the kind of therapy (first-line and salvage) and the location of the trial, with a specific focus on Japan and other countries. The study incorporated adverse events as an extra metric for evaluation. This meta-analysis aimed to assess significant differences in outcomes between the two groups.
Quality Assessment and Statistical Analysis
An independent researcher used the Cochrane risk-of-bias tool, RoB 2.0 to assess quality (Appendix). Forest plots and statistical analyses were conducted with ReviewManager (RevMan) 5.4 (2020; The Cochrane Collaboration, London, United Kingdom). The pooled effect size was calculated using forest plots with random or fixed effects. When I2 was less than 50%, a fixed-effects model was used; otherwise, a random-effects model was used. Publication bias was assessed using a funnel plot (Figure 2). A p-value <0.05 indicated statistical significance.
Figure 1. Quality Assessment .
Figure 2. Funnel plot of comparison of P-CABs vs PPIs, with regard to ITT.
P-CABs: potassium-competitive acid blockers; PPIs: proton pump inhibitors; ITT: intention-to-treat
Results
Figure 3 provides a visual representation of the process through which studies were chosen for inclusion in our analysis. Initially, our search yielded 326 studies from which we identified and eliminated duplicate records; 272 studies with irrelevant titles and abstracts were excluded from consideration. Fifty-four studies were chosen for further evaluation due to their relevance to the subject matter. Subsequently, an additional 40 studies were excluded. Ultimately, our final selection comprised 14 RCTs.
Figure 3. PRISMA Flow Chart.
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Table 2 shows the baseline characteristics of all included studies. The study period for the included studies ranged from 2012-2023. All of the studies were conducted in Asia, primarily in China and Japan.
Table 2. Baseline characteristics of the included studies.
VPZ: vonoprazan; OPZ: omeprazole; RPZ: rabeprazole; ESO: esomeprazole; LPZ: lansoprazole; A: amoxicillin; C: clarithromycin; M: metronidazole; S: sitafloxcin; TPZ: tegoprazan; bd: bis in die (twice daily)
| Author | Year | Country | Study period | Dosage of P-CAB | Dosage of antibiotics | Dosage of PPI |
| Hou et al. (45) | 2022 | China, South Korea, Taiwan, and the Philippines | 2017-2019 | VPZ 20 mg, bd, 14 days | A 1000 mg bd, 14 days C 500 mg bd, 14 days | LPZ 30 mg, bd, 14 days |
| Ang et al. (46) | 2022 | Singapore | 2019-2021 | VPZ 20 mg, bd, 7 days | A 1000 mg, bd C 500 mg, bd (For 7 or 14 days) | OPZ 20 mg, bd, 14 days ESO 20 mg, bd, 14 days RBZ 20 mg, bd, 14 days |
| Kim et al. (47) | 2023 | South Korea | 2020-2021 | TPZ 50 mg, bd, 14 days | Tetracycline 500 mg, qid, 14 days M 500 mg tid, 14 days | LPZ 30 mg, bd, 14 days |
| Hu et al. (48) | 2023 | China | 2021-2022 | VPZ 20 mg, bd, 14 days | A 1000 mg, tid or bd, 14 days M 400 mg, qid, 14 days | ESO 20 mg, bd, 14 days |
| Choi et al. (49) | 2022 | South Korea | TPZ 50 mg, bd, 7 days | A 1000 mg, bd, 7 days C 500 mg, bd, 7 days | LPZ 30 mg, bd, 7 days | |
| Lu et al. (50) | 2023 | China | 2021 | VPZ 20 mg, bd, 10 days or 14 days | A 1000 mg, bd, 10 days or 14 days | ESO 20 mg, bd, 14 days |
| Chen et al. (51) | 2023 | China | 2021-2022 | VPZ 20 mg, bd, 14 days | A 1000 mg, bd, 14 days C 500mg, bd, 14 days | RPZ 10 mg, bd, 14 days |
| Bunchorntavakul et al. (39) | 2021 | Thailand | 2019-2021 | VPZ 20 mg, bd, 7 days | A 1000 mg bd ,C 500 mg bd, 7 days or 14 days | OPZ 20 mg, bd, 14 days |
| Hojo et al. (41) | 2020 | Japan | 2015-2017 | VPZ 20 mg, bd, 7 days | A 750 mg bd, 7 days M 250 mg, bd, 7 days | RPZ 10 mg, bd, 7 days |
| Park et al. (42) | 2020 | Korea | 2013 | YH4808 200 mg, bd, 7 days | A 1000 mg bd, 7 days C 500 mg bd, 7 days | ESO 20 mg, bd, 7 days |
| Murakami et al. (44) | 2016 | Japan | 2012-2013 | VPZ 20 mg, bd, 7 days | A 750 mg bd, 7 days C 200 or 400 mg, bd, 7 days | LPZ 30 mg, bd, 7 days |
| Maruyama et al. (52) | 2017 | Japan | 2015-2016 | VPZ 20 mg, bd, 7 days | A 750 mg bd, 7 days C 200 or 400 mg, bd, 7 days | RPZ 20 mg or LPZ 30 mg bd, 7 days |
| Sue et al. (53) | 2019 | Japan | 2015-2017 | VPZ 20 mg, bd, 7 days | A 750 mg, bd, 7 days S 100 mg, bd, 7 days | LPZ 30 mg, bd, 7 days ESO 20 mg, bd, 7 days RPZ 10 mg, bd, 7 days |
| Sue et al. (54) | 2018 | Japan | 2015-2016 | VPZ 20 mg, bd, 7 days | A 750 mg, bd, 7 days C 200, bd, 7 days | LPZ 30 mg, bd, 7 days ESO 20 mg, bd, 7 days RPZ 10 mg or 400 mg, bd, 7 days |
Results of Intervention: Eradication Rate Assessed by ITT Analysis
Subgroup analysis based on the type of therapy: A total of 13 RCTs assessed the outcome of the eradication rate by ITT analysis, revealing significant overall results favoring the P-CAB group over the PPI group (risk ratio (RR)=1.09; 95%CI: 1.02-1.16; P= 0.01; I2= 65%). The results were consistent for the subgroup of first-line eradication therapy (RR=1.09; 95%CI: 1.02-1.16; P= 0.01; I2= 67%). However, no significant differences were observed between the two groups for salvage therapy (RR=1.11; 95%CI: 0.69-1.78; P= 0.66; I2= 73%) (Figure 4).
Figure 4. Forest plot comparing P-CABs and PPIs with regard to ITT.
Subgroup analysis based on the country in which the study was conducted: Incorporating a total of 13 RCTs that evaluated eradication rates through an ITT analysis, the findings indicated significant overall results in favor of the P-CAB group compared to the PPI group (RR=1.09; 95%CI: 1.02-1.16; P= 0.01; I2= 65%). These results remained consistent when examining the subgroup specific to Japan (RR=1.21; 95%CI: 1.08-1.34; P< 0.0006; I2= 45%). However, for the remaining countries, no significant differences were detected between the two groups (RR=1.03; 95%CI: 0.99-1.07; P= 0.19; I2= 0%) (Figure 5).
Figure 5. Forest plot comparing P-CABs and PPIs with regard to ITT subgroup based on countries.
References: [39,41,42,44,46-54]
P-CAB: potassium-competitive acid blocker; PPI: proton-pump inhibitor; ITT: intention-to-treat
Results of Intervention: Eradication Rate Assessed by PPA
Subgroup analysis based on the type of therapy: Thirteen RCTs were conducted to evaluate eradication rates using a PPA. The results demonstrated significant overall findings, with a preference for the P-CAB group over the PPI group (RR=1.08; 95%CI: 1.02-1.15; P= 0.006; I2= 74%). These results remained consistent when examining the subgroup focused on first-line eradication therapy (RR=1.08; 95%CI: 1.02-1.14; P= 0.01; I2= 76%). However, for salvage therapy (RR=1.20; 95%CI: 0.82-1.75; P= 0.34; I2= 69%), no significant differences were observed between the two groups (Figure 6).
Figure 6. Forest plot of comparison of P-CABs vs PPIs with regard to PPA.
References: [39,41,42,44,46-54]
P-CAB: potassium-competitive acid blocker; PPI: proton-pump inhibitor; PPA: per-protocol analysis
Subgroup analysis based on the country in which the study was conducted: Pooling data from a total of 13 RCTs that assessed eradication rates using a PPA, our analysis revealed significant overall results favoring the P-CAB group over the PPI group (RR=2.02; 95%CI: 1.33-3.08; P= 0.001; I2= 49%). These findings remained consistent when we analyzed the subgroup-specific to Japan (RR=3.33; 95%CI: 1.83-6.06; P< 0.0001; I2= 35%). However, for the other countries included in the study, no significant differences were identified between the two groups (RR=1.35; 95%CI: 0.96-1.90; P= 0.09; I2= 0%) (Figure 7).
Figure 7. Forest plot comparing P-CABs and PPIs with regard to PPA subgroup based on countries.
References: [39,41,42,44,46-54]
P-CAB: potassium-competitive acid blocker; PPI: proton-pump inhibitor; PPA: per-protocol analysis
Adverse Events
Eleven RCTs reported adverse events following the administration of P-CABs and PPIs. No significant difference was found between the two groups (RR=0.98; 95%CI: 1.14-0.93; P= 0.78; I2= 63%) (Figure 8).
Figure 8. Forest plot comparing P-CABs and PPIs with regard to adverse events.
P-CAB: potassium-competitive acid blocker; PPI: proton-pump inhibitor
Discussion
The current meta-analysis compares P-CABs to PPIs in eradicating H. pylori and includes both the ITT analysis and the PPA. In the ITT analysis, the overall results favored P-CABs, and the results of the subgroup first-line treatment within the ITT analysis remained consistent. However, no significant difference was found between the two groups for the subgroup of salvage eradication therapy within the ITT analysis. Another subgroup analysis was conducted within the ITT analysis to determine the effect of the country in which the study was conducted on the eradication rate, revealing P-CABs as the superior therapy over PPIs overall and within the subgroup of Japan. The subgroup of other countries did not yield significant results. In the PPA, the overall findings favored P-CABs, and this preference persisted when examining the subgroup focused on first-line treatment within the PPA. However, for the subgroup of salvage eradication therapy within the PPA, no statistically significant difference was observed between the two groups. Another subgroup analysis was conducted within the PPA to assess the impact of the study's location on the eradication rate. This analysis revealed P-CABs as the superior therapy over PPIs both in the overall study population and within the subgroup of Japan. However, the subgroup comprising other countries did not yield statistically significant results. Regarding adverse events, no significant results were obtained.
Previous meta-analyses have been conducted to evaluate the efficacy of P-CABs and PPIs in the eradication of H. pylori. Consistent with the findings of our study, a meta-analysis by Zhang et al. showed that P-CABs were more effective than PPIs as the first-line treatment for H pylori eradication (RR=1.18; 95%CI=1.10-1.28; p < 0.0001), particularly in Japanese patients [38]. However, this study only included seven RCTs, whereas our meta-analysis incorporated 14 RCTs with a larger sample size and patients from different Asian countries. Simadibrata et al. also revealed similar results, favoring the P-CABs group over PPIs in eradicating H. pylori (RR 1.13; 95%CI 1.04-1.22) [37]. Comparable results were shown by a meta-analysis conducted by Jung et al., revealing that the vonoprazan-based triple therapy showed superior efficacy in terms of H. pylori eradication compared to the PPI-based triple therapy (RR 1.19; 95%CI = 1.15-1.24) [36]. Additionally, the vonoprazan-based triple therapy showed comparable tolerability and incidence of adverse events (RR 1.02; 95%CI = 0.78-1.34). The current meta-analysis was unsuccessful in reporting significant effects of either of these medications on adverse events as well.
The effectiveness of H. pylori eradication is contingent upon maintaining stomach pH levels above 4.0 [55]. Vonoprazan is recognized for its capacity to sustain its acid-inhibitory activity regardless of the pH level in the gastric region, thus keeping its effectiveness in acidic conditions and preventing degradation [56]. In contrast to traditional PPIs, vonoprazan has a distinct mechanism of action that does not rely on acid activation [57]. This compound is characterized by its quick absorption in the colon, leading to efficient suppression of acid release [26]. Additionally, it should be noted that the effectiveness of vonoprazan is unaffected by meal timing, resulting in consistent medication concentrations in the bloodstream [58]. The plasma half-life of vonoprazan at a 20 mg dose is reported to be significantly longer compared to that of conventional PPIs [59]. These attributes play a significant role in achieving high eradication rates by sustaining higher pH levels.
Vonoprazan demonstrates the ability to elevate intragastric pH levels to a value exceeding 4.0 within a time frame of four hours following the initial administration in humans [59]. This creates a stable environment for preserving the effectiveness of amoxicillin and clarithromycin. Less acidity promotes bacterial growth, making them more sensitive to acid-sensitive medications like clarithromycin and amoxicillin [58]. This may provide an explanation for the observed superiority of a P-CAB-based treatment over a PPI-based regimen in patients with clarithromycin-resistant strains [44]. Furthermore, combining clarithromycin with vonoprazan leads to higher vonoprazan levels. This is attributed to clarithromycin's inhibition of the CYP3A4 enzyme, which plays a key role in metabolizing P-CAB [60].
The use of P-CABs in the treatment of H. pylori infection has important clinical and scientific ramifications. Clinical evidence suggests that P-CAB-based therapy may be an effective choice for the initial treatment of H. pylori due to its superiority, particularly in Japanese patients. This discovery might affect clinical recommendations and treatment strategies, improving patient outcomes. In terms of research, the examination of P-CABs in various geographic contexts emphasizes the significance of taking regional variations into account when creating treatment options. A customized approach to H. pylori eradication therapy may be made possible by further investigation into the processes underpinning P-CAB efficacy and its potential for personalized medicine methods. Studies comparing P-CABs to conventional therapies can provide a more thorough picture of the long-term effects and cost-effectiveness of P-CABs. Studies comparing the effectiveness and cost-efficiency of P-CABs to conventional treatments can also help us gain a deeper grasp of their therapeutic relevance.
The current meta-analysis demonstrates the benefits of P-CAB-based eradication therapy. However, it also has limitations. The research was exclusively conducted in Asian nations, which may have introduced selection bias due to genetic gastric pH and regional food. Second, antibiotic resistance was not examined in the study, and salvage therapy used different antibiotics. There were small sample sizes comparing P-CABs and PPIs in salvage therapy, especially in non-Japanese populations.
Conclusions
P-CAB-based triple therapy demonstrates superior efficacy compared to PPI-based triple therapy when used as the initial treatment for H. pylori eradication, especially in Japanese patients. However, in the context of salvage therapy, there is no significant difference in efficacy between the two treatments. Furthermore, the tolerability of P-CAB-based and PPI-based triple therapy is similar, with a comparable incidence of adverse events.
The authors have declared that no competing interests exist.
Author Contributions
Concept and design: Faraz Saleem, Omer Usman, Tafseer Zahra, Sandipkumar S. Chaudhari, Gopi Sairam Reddy Mulaka, Rumaisa Masood, Saima Batool, Abdullah Shah
Acquisition, analysis, or interpretation of data: Faraz Saleem, Omer Usman, Tafseer Zahra, Sandipkumar S. Chaudhari, Gopi Sairam Reddy Mulaka, Rumaisa Masood, Saima Batool, Abdullah Shah
Drafting of the manuscript: Faraz Saleem, Omer Usman, Tafseer Zahra, Sandipkumar S. Chaudhari, Gopi Sairam Reddy Mulaka, Rumaisa Masood, Saima Batool, Abdullah Shah
Critical review of the manuscript for important intellectual content: Faraz Saleem, Omer Usman, Tafseer Zahra, Sandipkumar S. Chaudhari, Gopi Sairam Reddy Mulaka, Rumaisa Masood, Saima Batool, Abdullah Shah
Supervision: Faraz Saleem, Tafseer Zahra, Gopi Sairam Reddy Mulaka, Saima Batool, Abdullah Shah
References
- 1.Role of toll-like receptors in Helicobacter pylori infection and immunity. Smith SM. World J Gastrointest Pathophysiol. 2014;5:133–146. doi: 10.4291/wjgp.v5.i3.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Helicobacter pylori: ulcers and more: the beginning of an era. Lacy BE, Rosemore J. J Nutr. 2001;131:2789–2793. doi: 10.1093/jn/131.10.2789S. [DOI] [PubMed] [Google Scholar]
- 3.Helicobacter pylori Infection. Crowe SE. N Engl J Med. 2019;380:1158–1165. doi: 10.1056/NEJMcp1710945. [DOI] [PubMed] [Google Scholar]
- 4.Helicobacter pylori and extragastric diseases: a review. Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. World J Gastroenterol. 2018;24:3204–3221. doi: 10.3748/wjg.v24.i29.3204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Clinical practice. Helicobacter pylori infection. McColl KE. N Engl J Med. 2010;362:1597–1604. doi: 10.1056/NEJMcp1001110. [DOI] [PubMed] [Google Scholar]
- 6.Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. Watari J, Chen N, Amenta PS, et al. World J Gastroenterol. 2014;20:5461–5473. doi: 10.3748/wjg.v20.i18.5461. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Malfertheiner P, Megraud F, O'Morain CA, et al. Gut. 2017;66:6–30. doi: 10.1136/gutjnl-2016-312288. [DOI] [PubMed] [Google Scholar]
- 8.Kyoto global consensus report on Helicobacter pylori gastritis. Sugano K, Tack J, Kuipers EJ, et al. Gut. 2015;64:1353–1367. doi: 10.1136/gutjnl-2015-309252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Schistosomes, liver flukes and Helicobacter pylori. https://pubmed.ncbi.nlm.nih.gov/7715068/ IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241. [PMC free article] [PubMed] [Google Scholar]
- 10.Helicobacter pylori infection and the risk of gastric carcinoma. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. N Engl J Med. 1991;325:1127–1131. doi: 10.1056/NEJM199110173251603. [DOI] [PubMed] [Google Scholar]
- 11.Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Graham DY. Gastroenterology. 2015;148:719–731. doi: 10.1053/j.gastro.2015.01.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Helicobacter pylori: perspectives and time trends. Malfertheiner P, Link A, Selgrad M. Nat Rev Gastroenterol Hepatol. 2014;11:628–638. doi: 10.1038/nrgastro.2014.99. [DOI] [PubMed] [Google Scholar]
- 13.Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Sugano K. Gastric Cancer. 2019;22:435–445. doi: 10.1007/s10120-018-0876-0. [DOI] [PubMed] [Google Scholar]
- 14.Age-specific incidence of Helicobacter pylori. Rowland M, Daly L, Vaughan M, Higgins A, Bourke B, Drumm B. Gastroenterology. 2006;130:65–72. doi: 10.1053/j.gastro.2005.11.004. [DOI] [PubMed] [Google Scholar]
- 15.Effect of age and Helicobacter pylori infection on gastric acid secretion. Haruma K, Kamada T, Kawaguchi H, et al. J Gastroenterol Hepatol. 2000;15:277–283. doi: 10.1046/j.1440-1746.2000.02131.x. [DOI] [PubMed] [Google Scholar]
- 16.Towards understanding of gastric cancer based upon physiological role of gastrin and ECL cells. Waldum H, Mjønes P. Cancers (Basel) 2020;12:3477. doi: 10.3390/cancers12113477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Treatment of Helicobacter pylori infection: current and future insights. Safavi M, Sabourian R, Foroumadi A. World J Clin Cases. 2016;4:5–19. doi: 10.12998/wjcc.v4.i1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.A report card to grade Helicobacter pylori therapy. Graham DY, Lu H, Yamaoka Y. Helicobacter. 2007;12:275–278. doi: 10.1111/j.1523-5378.2007.00518.x. [DOI] [PubMed] [Google Scholar]
- 19.Antibiotic treatment for Helicobacter pylori: is the end coming? Kim SY, Choi DJ, Chung JW. World J Gastrointest Pharmacol Ther. 2015;6:183–198. doi: 10.4292/wjgpt.v6.i4.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.The optimal first-line therapy of Helicobacter pylori infection in year 2012. Kuo CH, Kuo FC, Hu HM, et al. Gastroenterol Res Pract. 2012;2012:168361. doi: 10.1155/2012/168361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Optimal first-line treatment for Helicobacter pylori infection: recent strategies. Lee JY, Park KS. Gastroenterol Res Pract. 2016;2016:9086581. doi: 10.1155/2016/9086581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.ACG clinical guideline: treatment of Helicobacter pylori infection. Chey WD, Leontiadis GI, Howden CW, Moss SF. Am J Gastroenterol. 2017;112:212–239. doi: 10.1038/ajg.2016.563. [DOI] [PubMed] [Google Scholar]
- 23.Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Fallone CA, Moss SF, Malfertheiner P. Gastroenterology. 2019;157:44–53. doi: 10.1053/j.gastro.2019.04.011. [DOI] [PubMed] [Google Scholar]
- 24.First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Yeo YH, Shiu SI, Ho HJ, et al. Gut. 2018;67:20–27. doi: 10.1136/gutjnl-2016-311868. [DOI] [PubMed] [Google Scholar]
- 25.Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Dang BN, Graham DY. Nat Rev Gastroenterol Hepatol. 2017;14:383–384. doi: 10.1038/nrgastro.2017.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. Aliment Pharmacol Ther. 2015;42:1315–1326. doi: 10.1111/apt.13414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Echizen H. Clin Pharmacokinet. 2016;55:409–418. doi: 10.1007/s40262-015-0326-7. [DOI] [PubMed] [Google Scholar]
- 28.Update on the use of vonoprazan: a competitive acid blocker. Graham DY, Dore MP. Gastroenterology. 2018;154:462–466. doi: 10.1053/j.gastro.2018.01.018. [DOI] [PubMed] [Google Scholar]
- 29.Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. Miyazaki H, Igarashi A, Takeuchi T, et al. J Gastroenterol Hepatol. 2019;34:1316–1328. doi: 10.1111/jgh.14664. [DOI] [PubMed] [Google Scholar]
- 30.Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Lyu QJ, Pu QH, Zhong XF, Zhang J. Biomed Res Int. 2019;2019:9781212. doi: 10.1155/2019/9781212. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Efficacy of vonoprazan-based triple therapy for Helicobacter pylori eradication: a multicenter study and a review of the literature. Tanabe H, Ando K, Sato K, et al. Dig Dis Sci. 2017;62:3069–3076. doi: 10.1007/s10620-017-4664-1. [DOI] [PubMed] [Google Scholar]
- 32.Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Shinozaki S, Nomoto H, Kondo Y, et al. Kaohsiung J Med Sci. 2016;32:255–260. doi: 10.1016/j.kjms.2016.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Vonoprazan: first global approval. Garnock-Jones KP. Drugs. 2015;75:439–443. doi: 10.1007/s40265-015-0368-z. [DOI] [PubMed] [Google Scholar]
- 34.Potent acid suppression with PPIs and P-CABs: what's new? Hunt RH, Scarpignato C. Curr Treat Options Gastroenterol. 2018;16:570–590. doi: 10.1007/s11938-018-0206-y. [DOI] [PubMed] [Google Scholar]
- 35.The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Scarpignato C, Hunt RH. Curr Opin Gastroenterol. 2019;35:344–355. doi: 10.1097/MOG.0000000000000543. [DOI] [PubMed] [Google Scholar]
- 36.Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Jung YS, Kim EH, Park CH. Aliment Pharmacol Ther. 2017;46:106–114. doi: 10.1111/apt.14130. [DOI] [PubMed] [Google Scholar]
- 37.A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. Simadibrata DM, Syam AF, Lee YY. J Gastroenterol Hepatol. 2022;37:2217–2228. doi: 10.1111/jgh.16017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials. Zhang M, Pang M, Zhang M. Clinics (Sao Paulo) 2022;77:100058. doi: 10.1016/j.clinsp.2022.100058. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. Bunchorntavakul C, Buranathawornsom A. J Gastroenterol Hepatol. 2021;36:3308–3313. doi: 10.1111/jgh.15700. [DOI] [PubMed] [Google Scholar]
- 40.Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: is superiority an illusion? Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Helicobacter. 2017;22 doi: 10.1111/hel.12438. [DOI] [PubMed] [Google Scholar]
- 41.Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection. Hojo M, Asaoka D, Takeda T, et al. Therap Adv Gastroenterol. 2020;13:1756284820966247. doi: 10.1177/1756284820966247. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects. Park H, Kim CO, Kim M, Lim Y, Lee WY, Yoon S, Park MS. Transl Clin Pharmacol. 2020;28:136–146. doi: 10.12793/tcp.2020.28.e16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Page MJ, McKenzie JE, Bossuyt PM, et al. BMJ. 2021;372:0. doi: 10.1186/s13643-021-01626-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Gut. 2016;65:1439–1446. doi: 10.1136/gutjnl-2015-311304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. Hou X, Meng F, Wang J, et al. J Gastroenterol Hepatol. 2022;37:1275–1283. doi: 10.1111/jgh.15837. [DOI] [PubMed] [Google Scholar]
- 46.Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Ang D, Koo SH, Chan YH, et al. Aliment Pharmacol Ther. 2022;56:436–449. doi: 10.1111/apt.17070. [DOI] [PubMed] [Google Scholar]
- 47.Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: a randomized, double-blind, active-controlled study. Kim JS, Ko W, Chung JW, Kim TH. Helicobacter. 2023;28:0. doi: 10.1111/hel.12977. [DOI] [PubMed] [Google Scholar]
- 48.Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China. Hu J, Mei H, Su NY, et al. Helicobacter. 2023;28:0. doi: 10.1111/hel.12970. [DOI] [PubMed] [Google Scholar]
- 49.Triple therapy based on tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: a randomized, double-blind, phase iii, clinical trial. Choi YJ, Lee YC, Kim JM, et al. Gut Liver. 2022;16:535–546. doi: 10.5009/gnl220055. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: a single-center, open-label, noninferiority, randomized controlled trial. Lu L, Wang Y, Ye J, et al. Helicobacter. 2023;28:0. doi: 10.1111/hel.12940. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: a randomized controlled trial. Chen S, Shen W, Liu Y, Dong Q, Shi Y. Chin Med J (Engl) 2023;136:1690–1698. doi: 10.1097/CM9.0000000000002696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Vonoprazan-based regimen is more useful than ppi-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Maruyama M, Tanaka N, Kubota D, et al. Can J Gastroenterol Hepatol. 2017;2017:4385161. doi: 10.1155/2017/4385161. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S. J Gastroenterol Hepatol. 2019;34:686–692. doi: 10.1111/jgh.14456. [DOI] [PubMed] [Google Scholar]
- 54.Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Sue S, Ogushi M, Arima I, et al. Helicobacter. 2018;23:0. doi: 10.1111/hel.12456. [DOI] [PubMed] [Google Scholar]
- 55.Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Sugimoto M, Furuta T, Shirai N, et al. Helicobacter. 2007;12:317–323. doi: 10.1111/j.1523-5378.2007.00508.x. [DOI] [PubMed] [Google Scholar]
- 56.A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N. J Pharmacol Exp Ther. 2011;337:797–804. doi: 10.1124/jpet.111.179556. [DOI] [PubMed] [Google Scholar]
- 57.1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. Hori Y, Imanishi A, Matsukawa J, et al. J Pharmacol Exp Ther. 2010;335:231–238. doi: 10.1124/jpet.110.170274. [DOI] [PubMed] [Google Scholar]
- 58.Gastric infection by Helicobacter pylori. Sachs G, Scott DR, Wen Y. Curr Gastroenterol Rep. 2011;13:540–546. doi: 10.1007/s11894-011-0226-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Jenkins H, Sakurai Y, Nishimura A, et al. Aliment Pharmacol Ther. 2015;41:636–648. doi: 10.1111/apt.13121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Effect of multiple oral doses of the potent CYP3A4 inhibitor clarithromycin on the pharmacokinetics of a single oral dose of vonoprazan: a phase I, open-label, sequential design study. Jenkins H, Jenkins R, Patat A. Clin Drug Investig. 2017;37:311–316. doi: 10.1007/s40261-016-0488-6. [DOI] [PubMed] [Google Scholar]